April 14, 2016

DSN examines chain pharmacy, including in-depth coverage of specialty pharmacy, orphan drugs and biosimilars, in this multi-page report.

 

December 30, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, specialty pharmacy and top trends, in this multi-page report.

December 9, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, technology, automation, prescription drug home delivery services and Web-based diabetes monitoring, in this multi-page report.

November 11, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, regulations, technology, automation and medication synchronization, in this multi-page report.

October 13, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

September 11, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

August 20, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

July 15, 2015

DSN examines chain pharmacy, including in-depth coverage of technology, automation, medication synchronization and generics, in this multi-page report.

June 15, 2015

DSN examines chain pharmacy, including in-depth coverage of technology, automation and generics, in this multi-page report.

May 19, 2015

DSN examines chain pharmacy — including in-depth coverage of retail clinics, generics, consolidations, kiosks and more — in this multi-page report.

April 20, 2015

DSN examines chain pharmacy — including in-depth coverage of provider status, generics, pharmacy deserts, point-of-care testing and more — in this multi-page report.

March 9, 2015

DSN examines chain pharmacy, including in-depth coverage of provider status, kiosks, Medicare and the GPhA elections, in this multi-page report.

February 24, 2015

The Food and Drug Administration is looking into enabling holders of abbreviated new drug applications to unilaterally update their generic drug product labels prior to any branded drug change. 

February 4, 2015

DSN examines chain pharmacy, including in-depth coverage of telehealth, generic drug prices, and the GPhA CEO to step down, as well as Uhl appointed director of OGD, in this multi-page report.

January 27, 2015

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.

January 5, 2015

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, as well as a Q&A with Owen Mumford's Travis Shaw, in this multi-page report.

December 12, 2014

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, as well as a look at FDA reform and its potential impact on healthcare costs, in this multi-page report.

November 18, 2014

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, as well as a look at the impact of the Hatch-Waxman act and Q&A's with industry leaders, in this multi-page report.

November 17, 2014

DSN spoke with Neas in late October to mark the 30th anniversary of the landmark Drug Price Competition and Patent Term Restoration Act — better known as the Hatch-Waxman Act. 

November 17, 2014

Thirty years ago, Democratic and Republican members of Congress hammered out a rare and prescient bipartisan compromise bill that transformed the pharmaceutical landscape forever and unleashed the modern generic drug industry. That law, known as the Hatch-Waxman Act, has proven to be one of the most far-reaching and impactful pieces of legislation ever to shape the American healthcare system.

October 15, 2014

As the Food and Drug Administration begins to explore ways to improve its user-fee program for generic drugs, the Generic Pharmaceutical Association and its members have weighed in with suggestions on how to shore up the law to ensure that it helps bring generics to market faster and provides benefits across the entire healthcare system.

September 24, 2014

In honor of the 30th anniversary of the Drug Price Competition and Patent Term Restoration Act — more commonly known as the Hatch Waxman Act — which enabled manufacturers to bring generic versions of pharmaceuticals to market more easily, GPHA president Ralph Neas issued a statement.

September 24, 2014

In celebration of the 30th anniversary of the enactment of the Drug Price Competition and Patent Term Restoration Act, also known as the “Hatch-Waxman” Act, the National Association of Chain Drug Stores issued a statement to reflect on the evolution of providing patient access to generic medications and noted that it is looking forward to further progress in the years ahead.

August 20, 2014

Despite creating a detailed plan to speed up the rate at which generic drug applications are reviewed, experts say a backlog has developed at the Food and Drug Administration’s Office of Generic Drugs.